evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

131 questions · 131 findings · 55 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 10 · 7.6%GRADE not reported 10 · 7.6%Very low 31 · 23.7%Low 39 · 29.8%Moderate 31 · 23.7%High 10 · 7.6%

Febuxostat 80 mg/day vs placebo

Withdrawals due to adverse events · people with chronic gout

Febuxostat 80 mg/day showed no clear difference in discontinuations due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Febuxostat 40 mg/day vs allopurinol

Withdrawals due to adverse events · people with chronic gout

Febuxostat 40 mg/day showed no clear difference in discontinuations due to adverse events compared with allopurinol (high certainty).

1 finding from 1 review

Febuxostat 80 mg/day vs allopurinol

Withdrawals due to adverse events · people with chronic gout

Febuxostat 80 mg/day showed no clear difference in discontinuations due to adverse events compared with allopurinol (moderate certainty).

1 finding from 1 review

Febuxostat 40 mg/day vs placebo

Withdrawals due to adverse events · people with chronic gout

Febuxostat 40 mg/day showed no clear difference in discontinuations due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Febuxostat 120 mg/day vs placebo

Withdrawals due to adverse events · patients with chronic cout

Febuxostat 120 mg/day showed no clear difference in discontinuations due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Febuxostat 120 mg/day vs allopurinol

Withdrawals due to adverse events · people with chronic gout

Febuxostat 120 mg/day showed no clear difference in discontinuations due to adverse events compared with allopurinol (high certainty).

1 finding from 1 review

Intermittent/cyclic etidronate 400 mg/day vs placebo

Withdrawals due to adverse events · postmenopausal women with a higher risk for fracturesa

It is very uncertain whether intermittent/cyclic etidronate 400 mg/day changes withdrawals due to adverse events compared with placebo (very low certainty).

1 finding from 1 review

Donepezil 10 mg/day vs placebo

Risk for at least one adverse event per patient · people with severe Alzheimer's disease

Donepezil 10 mg/day probably leads to higher incidence of adverse events (at least one adverse event by 24 weeks) compared with placebo (moderate certainty).

1 finding from 1 review

Donepezil 10 mg/day vs placebo

Risk for at least one adverse event per patient · people with Alzheimer's disease

Donepezil 10 mg/day probably leads to higher incidence of adverse events (at least one adverse event by 26 weeks) compared with placebo (moderate certainty).

1 finding from 1 review

Pyronaridine‐artesunate (PY‐AS) vs mefloquine plus artesunate (MQ + AS)

Serious adverse events (42 days) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) showed no clear difference in serious adverse events (42 days) compared with mefloquine plus artesunate (MQ + AS) (low certainty).

1 finding from 1 review

Pyronaridine‐artesunate (PY‐AS) vs artemether‐lumefantrine (AL)

Serious adverse events (42 days) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) showed no clear difference in serious adverse events (42 days) compared with artemether‐lumefantrine (AL) (low certainty).

1 finding from 1 review

RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies (EpAbs) vs saline placebo

Serious adverse events (by day 28) · individuals with moderate or severe COVID‐19

RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in serious adverse events (by day 28) compared with saline placebo (low certainty).

1 finding from 1 review

Intervention not reported

Serious adverse events up to day 45 · non‐hospitalised adults with mild COVID‐19

The intervention showed no clear difference in serious adverse events up to day 45 (low certainty).

1 finding from 1 review